Abstract:Nasopharyngeal carcinoma (NPC) is consistently associated with Epstein-Barr virus (EBV) infection in regions in which it is endemic, including Southern China and Southeast Asia. The high mortality rates of NPC patients with advanced and recurrent disease highlight the urgent need for effective treatments. While recent genomic studies have revealed few druggable targets, the unique interaction between the EBV infection and host cells in NPC strongly implies that targeting EBV may be an efficient approach to cure this virus-associated cancer. Key features of EBV-associated NPC are the persistence of an episomal EBV genome and the requirement for multiple viral latent gene products to enable malignant transformation. Many translational studies have been conducted to exploit these unique features to develop pharmaceutical agents and therapeutic strategies that target EBV latent proteins and induce lytic reactivation in NPC. In particular, inhibitors of the EBV latent protein EBNA1 have been intensively explored, because of this protein's essential roles in maintaining EBV latency and viral genome replication in NPC cells. In addition, recent advances in chemical bioengineering are driving the development of therapeutic agents targeting the critical functional regions of EBNA1. Promising therapeutic effects of the resulting EBNA1-specific inhibitors have been shown in EBV-positive NPC tumors. The efficacy of multiple classes of EBV lytic inducers for NPC cytolytic therapy has also been long investigated. However, the lytic-induction efficiency of these compounds varies among different EBV-positive NPC models in a cell-context-dependent manner. In each tumor, NPC cells can evolve and acquire somatic changes to maintain EBV latency during cancer progression. Unfortunately, the poor understanding of the cellular mechanisms regulating EBV latency-to-lytic switching in NPC cells limits the clinical application of EBV cytolytic treatment. In this review, we discuss the potential approaches for improvement of the above-mentioned EBV-targeting strategies.

Investigational drugs for nasopharyngeal carcinoma

Nasopharyngeal carcinoma: an evolving paradigm

Immunotherapy for EBV-Associated Nasopharyngeal Carcinoma.

Novel systemic therapeutic for nasopharyngeal carcinoma

Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma

Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma

Novel therapy for nasopharyngeal carcinoma--where are we

Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)

Early Stage and Locally Advanced Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Going?

Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma

Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options

Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes

Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy

Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect

Targeting the crosstalk of epigenetic modifications and immune evasion in nasopharyngeal cancer

Precision Medicine for Nasopharyngeal Cancer—A Review of Current Prognostic Strategies

Multimodality Management of EBV-Associated Nasopharyngeal Carcinoma

A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy

Progress in the clinical development of investigational systemic agents for recurrent and metastatic nasopharyngeal carcinoma

Recent advances in early detection of nasopharyngeal carcinoma

Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment